Home > News > Top Israeli tech transfer chief wooed away by Harvard
March 27th, 2005
Top Israeli tech transfer chief wooed away by Harvard
"Grants alone cannot support cutting-edge research and take an innovation to the level at which companies will develop a product for both economic gains and the public good," Ramot's CEO Isaac Kohlberg told ISRAEL21c. So he came up with an ingenious idea to deal with the shortfall of funds needed to hoist an innovation from the lab to the marketplace: an in-house VC fund. The idea has proved so successful, that Harvard University recently scooped up Kohlberg to take on a newly created position - Associate Provost and Chief Technical Development Officer, a post he begins in May.
Among the nanotechnology discoveries that have received a boost is the work of Professor Rimona Margalit who is using a coating of nanoparticles to enable drug targeting directly to a tumor.
Another partnership project headed by Professor Ehud Gazit focuses on the prevention of amyloid aggregation (build up) in various diseases. Fine, threadlike amyloid fibrils are waxy, translucent substances composed primarily of protein fibers that are deposited in various organs in certain diseases. Curiously, the diseases are unrelated - Alzheimer's, prion (Mad Cow), and Type II Diabetes. Gazit and his team stumbled on another discovery while researching amyloids. His team observed the self-assembly formation of short aromatic peptides to form amyloid fibrils, virtual nanotubes.
GS7 Graphene Sensor maybe Solution in Fight Against Cancer January 25th, 2015
Nanotechnology in Energy Applications Market Research Report 2014-2018: Radiant Insights, Inc January 15th, 2015
'Mind the gap' between atomically thin materials December 23rd, 2014
A novel method for identifying the body’s ‘noisiest’ networks November 19th, 2014
Malaysian Nanotechnology Company Nanopac Innovation Ltd. lists on the NSX January 19th, 2015
Aspen Aerogels, Inc. to Present at the Needham Growth Conference January 8th, 2015
Blend Therapeutics Secures $21 Million Financing and Unveils Novel Pentarin™ Platform for Cancer Therapeutics: Company’s Technology and Expertise in Cancer R&D Evolve to Create New Class of Miniaturized Biologic Drug Conjugates (mBDCs) Encapsulated in Nanoparticles January 8th, 2015
Nanometrics to Announce Fourth Quarter and Full Year Financial Results on February 2, 2015 January 7th, 2015
New method allows for greater variation in band gap tunability: The method can change a material's electronic band gap by up to 200 percent January 31st, 2015
Evidence mounts for quantum criticality theory: Findings bolster theory that quantum fluctuations drive strange electronic phenomena January 30th, 2015
Everything You Need To Know About Nanopesticides January 30th, 2015
DNA nanoswitches reveal how life's molecules connect: An accessible new way to study molecular interactions could lower cost and time associated with discovering new drugs January 30th, 2015